The Company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP ...

Palatin (NYSE:PTN) said it has initiated a Phase 2 study of its drug bremelanotide in combination with tirzepatide for the treatment of obesity. The primary endpoint of the study is reduction in ...